DMARDs include methotrexate, sulfasalazine, leflunomide (Arava®), . in an individual patient of gastrointestinal damage versus potential cardiovascular risk factors. etanercept (Enbrel®, adalimumab (Humira ®), and infliximab (Remicade®), arthritis including psoriatic arthritis and other...